Russell Yanofsky

Advanced IBD fellow @UChicagoIBD | GI @UofTgastrohep | Internal medicine and MDCM @mcgillu

[Russell Yanofsky @RussellYanofsky]

Congrats @Agneshyan !!!

[Tauseef Ali MD, FACG AGAF FACP @ibdtweets]

📢 New Real-World Study on Rinvoq (Upadacitinib) Reinduction in IBD

🌸 A new prospective cohort from the University of Chicago IBD Center highlights an important clinical reality:

🔹 Up to 25% of patients who respond to UPA 45 mg induction lose response after dose reduction to 30 mg or 15 mg.
🔹 Reinduction with 45 mg recaptured clinical response in 80% of these patients.
🔹 Patients who stayed on 45 mg maintained remission far more often (94%) than those reduced again (26%).
🔹 No serious adverse events were reported with prolonged 45 mg use.

💡 Clinical takeaway:
Some IBD patients who lose response after dose reduction may benefit from reinduction and continued high-dose maintenance, especially those with refractory disease and multiple prior biologic failures.

@IBDPharmD @KrugCleveland
@SushilaDalal @jpekowmd @UChicagoIBD @AGA_CGH

Question for colleagues:

➡️ Are you seeing similar patterns of dose-dependent loss of response or need for prolonged high-dose therapy in your practice?

https://t.co/6gvpckTObE

[Russell Yanofsky @RussellYanofsky]

@JeongkukSeoMD @AmJGastro @IBDMD @UChicagoIBD Thanks!

[Russell Yanofsky @RussellYanofsky]

Check out our brief report in the @AmJGastro !

We report on 8 patients who developed an eczematous eruption following discontinuation of their JAK inhibitor, with 2 patients having biopsy-proven atopic dermatitis @IBDMD @UChicagoIBD

https://t.co/wqz9hgGutr

[Russell Yanofsky @RussellYanofsky]

@guthealthmd @AmJGastro @IBDMD @UChicagoIBD @laura_tee_mdgi @ptandonGI @ChhibbaTarun More data needed for sure. Important to consider this possibility vs. drug reaction to a new therapy. We discuss how we saw it before treatment change, persistence despite changing to a second therapy, and one patient even trialled stopping and restarting the JAK to test it out

[Russell Yanofsky @RussellYanofsky]

@AmJGastro @IBDMD @UChicagoIBD @guthealthmd @laura_tee_mdgi @ptandonGI @ChhibbaTarun @Agneshyan @IBDPharmD @amelia_kellar @SushilaDalal

[Russell Yanofsky @RussellYanofsky]

@AmJGastro @IBDMD @UChicagoIBD As JAKs are an effective therapy for AD, we propose that a subset of IBD patients may have latent susceptibility to AD, unmasked by therapy cessation and potentially triggered by an immune rebound effect

Thoughts/experience? @guthealthmd @laura_tee_mdgi @ptandonGI @ChhibbaTarun

[Russell Yanofsky @RussellYanofsky]

@AlexJ_Mathew @AmJGastro @IBDMD @UChicagoIBD Thanks Alex!

[Amelia Kellar @amelia_kellar]

Grateful to be a part of this important work defining ultrasound parameters for measuring bowel damage in Crohn’s Disease: The EXTENT Study: https://t.co/EwYFSDPatG
@CathyLuMD @bverstockt @RuneWilkens @MariangelaAllo3 @KrugCleveland @DrMikeDolinger @IBD_FloMD @JoanaTo62523004

[Russell Yanofsky @RussellYanofsky]

Our new meta-analysis in the Journal of IBD demonstrated that IBD was associated with EoE, independent of IBD subtype. Thanks to @ptandonGI for the mentorship and support throughout and the team for this great collaboration! @DrLexGI @ChhibbaTarun
https://t.co/2lDXwjcqFM

[Allan Detsky MD PhD CM @ADetsky]

The potential impact of this RCT is huge. First one to prove that exercise has benefits equal to many standard treatments for cancer. Wow! Congrats to #ChrisBooth, #KerryCourneya eg al. Go Canada! https://t.co/kQu014ki82

[Amelia Kellar @amelia_kellar]

The Crohn's and Colitis Foundation's Take Steps Walk is only 1 week away on June 8th! If you can't join us in person, please consider donating to our team, Intestinal Fortitude. Every dollar counts! @CrohnsColitisFn @UChicagoIBD
https://t.co/TNq9ntuK2N

[Russell Yanofsky @RussellYanofsky]

@MDankner @IBDMD @amelia_kellar @KrugCleveland @Klein_Jeremy @IBDPharmD @ashershaf Very important impact factor of 2!

[Russell Yanofsky @RussellYanofsky]

Introducing Gabe Yanofsky, the newest and youngest member of the @IBDMD research team! @amelia_kellar @KrugCleveland @Klein_Jeremy @IBDPharmD @ashershaf

[Russell Yanofsky @RussellYanofsky]

@AJourdan @IBDMD @amelia_kellar @KrugCleveland @Klein_Jeremy @IBDPharmD @ashershaf You make my day @AJourdan !

[Russell Yanofsky @RussellYanofsky]

@laura_tee_mdgi @IBDMD @amelia_kellar @KrugCleveland @Klein_Jeremy @IBDPharmD @ashershaf Thanks @laura_tee_mdgi ! He’s been doing his best to keep me sharp and ready for @UofTGastroHep by plenty of 💩 assessments!

[Agnes Ho @Agneshyan]

Ready to present our hard work on real-world experience of UPADACITINIB reinduction and high dose maintenance therapy to recapture disease response in inflammatory bowel disease!

#DDW2025
@UChicagoIBD

[Agnes Ho @Agneshyan]

Thrilled to have launched the Intestinal Ultrasound (IUS) service in Prince of Wales Hospital, Hong Kong and joined IBUS @BowelUltrasound as module 2 training center! Thank you @KrugCleveland and @amelia_kellar for the untiring guidance throughout the 6 months in UChicago!

#ibd

[Russell Yanofsky @RussellYanofsky]

Appreciate the opportunity to be part of this case and learn from @amelia_kellar, Sarah Stein, and @IBDMD about the intersection of Hermansky-Pudlak Syndrome, Crohn’s, and HS. Check out our case report here!

[Amelia Kellar @amelia_kellar]

Pleased to share this case of Hermansky-Pudlak Syndrome Complicated by Crohn's Disease and HS : ACG Case Reports Journal https://t.co/i6HorKp0U8 @RussellYanofsky @IBDMD @UChicagoMed

[David Choi, PharmD @IBDPharmD]

Tremfya is FDA approved for Crohn's disease! This has both IV (200 mg) and subq (400 mg) induction loading dose options followed by subq maintenance dose (100 mg or 200 mg). #GITwitter #IBD

https://t.co/y2Ick4bEcT

[Jonathan Segal @Jonathansegal85]

Poor form to attack @laura_tee_mdgi JK Rowling.

We should all be standing up for the rights of the trans community. There is no better advocate and role model than Laura.

I stand with her.